Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Shares in drugs giant AstraZeneca (AZN) looked perkier today as it reported a rise in sales and eased investor fears over the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60 ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-quarter and full-year ...